1174231-07-2

Usage

Uses

Used in Medicinal Chemistry:
(S)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-1H-pyrazol-3-amine is used as a potential pharmaceutical candidate for its diverse biological activities. (S)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-1H-pyrazol-3-amine's unique structure and chirality may contribute to its effectiveness in various therapeutic areas, including anti-inflammatory, anticancer, and antimicrobial properties.
Used in Drug Development:
In the pharmaceutical industry, (S)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-1H-pyrazol-3-amine is utilized as a lead compound for the development of new drugs. Its potential biological functions and therapeutic uses are under investigation, with the aim of identifying specific targets and mechanisms of action that could benefit patients in need of novel treatment options.
Used in Chemical Research:
(S)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-1H-pyrazol-3-amine serves as a subject of interest in chemical research, where scientists explore its synthesis, properties, and potential reactions with other molecules. Understanding the compound's behavior can lead to the discovery of new chemical entities and applications in various fields.

Upstream product

• 1191997-66-6 2-[1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-isoindole-1,3-dione 
• 1191453-79-8 1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-3-nitro-1H-pyrazole 

Downstream Products

• 1191995-13-7 (S)-2-[4-(2,3-dichloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191995-17-1 (S)-2-[4-(2-ethoxy-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191995-22-8 (S)-3-cyclopentyl-2-[4-(2,6-difluoro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-N-[1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-propionamide 
• 1191998-11-4 (S)-4-methyl-2-[2-oxo-4-(3-trifluoromethyl-phenoxy)-2,5-dihydro-pyrrol-1-yl]-pentanoic acid [1-((R)-2,2-dimethyl[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191998-18-1 (S)-2-[4-(3-chloro-2-fluoro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191998-32-9 (S)-2-[4-(4-methoxy-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191998-42-1 (S)-2-[4-(2,5-difluoro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191998-47-6 (S)-2-[4-(2,4-difluoro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191998-53-4 (S)-2-[4-(2-fluoro-5-methyl-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191998-65-8 (S)-2-[4-(3-ethoxy-2-fluoro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191995-51-3 (S)-2-[4-(3-ethoxy-2,6-difluoro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191995-53-5 (S)-2-[4-(2,6-difluoro-3-methoxy-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191995-58-0 (S)-4-methyl-2-(2-oxo-4-o-tolyloxy-2,5-dihydro-pyrrol-1-yl)-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 
• 1191997-42-8 (S)-2-[4-(2-chloro-3-methoxy-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide 

Relevant academic research and scientific papers

Deuterated pyrrolidone derivative Pharmaceutical compositions and uses thereof

The invention relates to a deuterated pyrrolidone derivative and a preparation method thereof, and also relates to application of the deuterated pyrrolidone derivative and a pharmaceutical composition thereof in treatment and prevention of metabolic disorder related diseases, and belongs to the field of medicines.

Preparation method of intermediate for synthesizing Dorzagliptin

The invention discloses a preparation method of an intermediate for synthesizing Dorzagliptin, and belongs to the technical field of organic synthesis application. A preparation method of (R)-1-((2, 2-dimethyl-1, 3-dioxolane-4-yl) methyl)-1H-pyrazole-3-ammonia is provided, a route without a protecting group is designed by starting from simple and accessible raw materials to obtain the target product (R)-1-((2, 2-dimethyl-1, 3-dioxolane-4-yl) methyl)-1H-pyrazole-3-ammonia. The method has the technical effects that the reaction process is shortened, the variety and the dosage of reagents are reduced, and amino protection and deprotection are avoided.

PHENYL ACETAMIDE DERIVATIVE

[Problems] To provide a compound which is useful as a GK activator. [Means for Solving Problems] The present inventors have conducted extensive studies on a phenylacetamide derivative, and as a result, have confirmed that a phenylacetamide derivative having sulfonyl group and cycloalkyl group on the phenyl group and having heteroaryl group on the nitrogen atom in the amide has an excellent GK activation action, thereby completing the present invention. The compound of the present invention is useful as an agent for treating diabetes, in particular, type II diabetes, since it has an excellent GK activation action.

PYRROLIDINONE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

PYRIDAZINONE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.